patients as low risk. However, negative and positive predictive values were generally low (online Technical Appendix Table) . Reasons for poor validation could include differences in applying the general EVD suspect case definition (integration of patients' contact history); in patient characteristics because organization and access to care for EVD and non-EVD illness was different (patients in holding centers or ETC); in the quality of data collection (symptoms are entirely self-reported); and in underlying diseases of EVD-negative patients.
Our findings underline the importance of external validation in various settings before risk scores are applied outside of the setting within which they were developed, as well as the need to incorporate patient contact history into predictive models. Point-of-care EVD diagnostic platforms can perform reliable confirmatory testing within 90 minutes (3). We argue that, by integrating rapid confirmatory testing in triage, providers can avoid classifying patients by their likelihood of infection with Ebola virus while waiting for laboratory confirmation.
